Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-10T19:26:11.915Z Has data issue: false hasContentIssue false
  • English
  • Français

A pharmacopsychometric overview of major depressive episodes in positive psychiatry

Published online by Cambridge University Press:  30 January 2018

P. Bech
P. Bech*
Affiliation:
Psychiatric Research Unit, Mental Health Centre North Zealand, University of Copenhagen, Hilleroed, Denmark
*
Correspondence should be addressed to: Per Bech, Psychiatric Research Unit, Mental Health Centre North Zealand, University of Copenhagen, Dyrehavevej 48, DK-3400, Hilleroed, Denmark. Phone: +45-38-64-30-95. Email: Per.bech@regionh.dk.
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

The use of the pharmacopsychometric triangle to enhance patient-reported well-being as the ultimate goal of treatment has most intensively been studied in patients with a major depressive episode.

Methods:

The review is structured on the pharmacopsychometric triangle in which the desired clinical effect of an antidepressive medication is balanced against the undesired side effects induced by this medication in terms of restored well-being. As a biological treatment, the antidepressive medication is compared clinically with both electroconvulsive therapy and psychological treatment.

Results:

In the process of this review, evidence from a dose–response study in patients suffering from a major depressive episode with an adequate duration and symptom severity has demonstrated that the dose–response relationship emerged when using the patient-reported well-being outcome rather than the symptomatic reduction as outcome.

Conclusion:

The pharmacopsychometric triangle is in patients with major depressive episodes providing important information within positive psychiatry.

Keywords

positive psychiatrypharmacopsychometric triangledepressive episodesantidepressantswell-being
Type
Review Article
Information
International Psychogeriatrics , Volume 30 , Special Issue 6: Social Health , June 2018 , pp. 833 - 841
Copyright
Copyright © International Psychogeriatric Association 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alves, L. P. C., Fleck, M. P. A., Boni, A. and Rocha, N. S. (2017). The major depressive disorder hierarchy: Rasch analysis of 6 items of the Hamilton depression scale covering the continuum of depressive syndrome. Plos One, 12, e0170000.Google Scholar
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5), 5th edn. Washington, DC: American Psychiatric Association.Google Scholar
Angst, J. (1961). A clinical analysis of the effects of tofranil in depression. Longitudinal and follow-up studies. Treatment of blood-relations. Psychopharmacologia, 2, 381–407.Google Scholar
Angst, J. (1996). The myths of psychopharmacology. In Healy, D. (ed.), The Psychopharmacologists (pp. 287–307). London: Altman, Chapman and Hall.Google Scholar
Bech, P. (1975). Mental illness and simulated driving: before and during treatment. Pharmakopsychiatrie Neuro-Psychopharmakologie, 8, 143–150.Google Scholar
Bech, P. (1993). Rating Scales for Psychopathology, Health Status and Quality of Life. A Compendium on Documentation in Accordance with the DSM-III-R and WHO Systems. Berlin: Springer.Google Scholar
Bech, P. (1998). Quality of Life in the Psychiatric Patient. London: Mosby-Wolfe.Google Scholar
Bech, P. (1999). Health-related quality of life measurements in the assessment of pain clinic results. Acta Anaesthesiologica Scandinavica, 43, 893–896.Google Scholar
Bech, P. (2012). Clinical Psychometrics. Oxford: Wiley Blackwell.Google Scholar
Bech, P. (2015). Clinical assessments of positive mental health. In Jeste, D. V. and Palmer, B. W. (eds.), Positive Psychiatry (pp. 127–143). Washington, DC: American Psychiatric Publishing.Google Scholar
Bech, P. (2016). Measurement-Based Care in Mental Disorders. New York: Springer.Google Scholar
Bech, P. et al. (1981). The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatrica Scandinavica, 63, 290–299.Google Scholar
Bech, P., Gram, L. F., Dein, E., Jacobsen, O., Vitger, J. and Bolwig, T. G. (1975). Quantitative rating of depressive states. Acta Psychiatrica Scandinavica, 51, 161–170.Google Scholar
Boyer, P. et al. (2008). Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. International Clinical Psychopharmacology, 23, 243–253.Google Scholar
Brown, W. A. (2013). The Placebo Effect in Clinical Practice. New York: Oxford University Press.Google Scholar
Brunnauer, A. et al. (2015). Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine. Pharmacopsychiatry, 48, 65–71.Google Scholar
Buckley, N. A., Dawson, A. H. and Isbister, G. K. (2014). Serotonin syndrome. BMJ, 348, g1626.Google Scholar
Cuijpers, P., Van Straten, A., Bohlmeijer, E., Hollon, S. D. and Andersson, G. (2010). The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychological Medicine, 40, 211–223.Google Scholar
DUAG (1990). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. Journal of Affective Disorders, 18, 289–299.Google Scholar
DUAG (1999). Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG). Clinical Pharmacology and Therapeutics, 66, 152–165.Google Scholar
Elkin, I. et al. (1989). National institute of mental health treatment of depression collaborative research program. General effectiveness of treatments. Archives of General Psychiatry, 46, 971–982.Google Scholar
Elkin, I., Gibbons, R. D., Shea, M. T. and Shaw, B. F. (1996). Science is not a trial (but it can sometimes be a tribulation). Journal of Consulting and Clinical Psychology, 64, 92–103.Google Scholar
Ellervik, C., Kvetny, J. and Bech, P. (2016). The relationship between sleep length and restorative sleep in major depression: results from the Danish general suburban population study. Psychother Psychosom, 85, 45–46.Google Scholar
Ellervik, C., Kvetny, J., Christensen, K. S., Vestergaard, M. and Bech, P. (2014). Prevalence of depression, quality of life and antidepressant treatment in the Danish general suburban population study. Nordic Journal of Psychiatry, 68, 507–512.Google Scholar
Fava, G. A., Tomba, E. and Bech, P. (2017). Clinical pharmacopsychology: conceptual foundations and emerging tasks. Psychotherapy and Psychosomatics, 86, 134–140.Google Scholar
Feinstein, A. R. (1987). Clinometric. New Haven: Yale University Press.Google Scholar
Gill, T. M. and Feinstein, A. R. (1994). A critical appraisal of the quality of quality-of-life measurements. JAMA, 272, 619–626.Google Scholar
Guidi, J., Tomba, E. and Fava, G. A. (2016). The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. The American Journal of Psychiatry, 173, 128–137.Google Scholar
Hall, T., Krahn, G. L., Horner-Johnson, W., Lamb, G. and Rehabilitation Research and Training Center Expert Panel on Health Measurement (2011). Examining functional content in widely used health-related quality of life scales. Rehabilitation Psychology, 56, 94–99.Google Scholar
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23, 56–62.Google Scholar
Hamilton, M. (1967). Development of a rating scale for primary depressive illness. The British Journal of Social and Clinical Psychology, 6, 278–296.Google Scholar
Haq, A. U., Sitzmann, A. F., Goldman, M. L., Maixner, D. F. and Mickey, B. J. (2015). Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. The Journal of Clinical Psychiatry, 76, 1374–1384.Google Scholar
Hattie, J. (2009). Visible Learning. A Synthesis of Over 800 Meta-Analyses Relating to Achievement, 1st edn. London: Routhledge.Google Scholar
Hays, R. D., Wells, K. B., Sherbourne, C. D., Rogers, W., and Spitzer, K. (1995). Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Archives of General Psychiatry, 52, 11–19.Google Scholar
Jarrett, R. B., Schaffer, M., McIntire, D., Witt-Browder, A., Kraft, D. and Risser, R. C. (1999). Treatment of atypical depression with cognitive therapy or phenelzine. Archives of General Psychiatry, 56, 431–437.Google Scholar
Jeste, D. V., Palmer, B. W., Rettew, D. C. and Boardman, S. (2015). Positive psychiatry: its time has come. The Journal of Clinical Psychiatry, 76, 675–683.Google ScholarPubMed
Johnstone, E. C. et al. (1980). The Northwick Park electroconvulsive therapy trial. Lancet, 2, 1317–1320.Google Scholar
Kendell, R. E. (1968). The Classification of Depressive Illnesses. London: Oxford University Press.Google Scholar
Kendell, R. E. (1981). The present status of electroconvulsive therapy. The British Journal of Psychiatry: The Journal of Mental Science, 139, 265–283.Google Scholar
Kraepelin, E. (1913). Psychiatrie. Bind 3. Leipzig: Barth.Google Scholar
Kramer, P. D. (2016). Ordinarily Well. The Case for Antidepressants. New York: Farrar, Straus and Giroux.Google Scholar
Lindstrom, E., Lewander, T., Malm, U., Malt, U. F., Lublin, H. and Ahlfors, U. G. (2001). Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia.Clinical validation of a self-rating version of the UKU side effect rating scale (UKU-SERS-Pat). Nordic Journal of Psychiatry, 55 (Suppl. 44), 5–69.Google Scholar
Lingjaerde, O., Ahlfors, U. G., Bech, P., Dencker, S. J. and Elgen, K. (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum, 334, 1–100.Google Scholar
Lucas-Carrasco, R., Allerup, P. and Bech, P. (2012). The validity of the WHO-5 as an early screening for apathy in an elderly population. Current Gerontology and Geriatrics Research, 2012, 171857.Google Scholar
Lundquist, G. (1945). Prognosis and course in manic-depressive psychosis. Acta Psychiatrica et Neurologica Scandinavica, 38(Suppl. 35), 1–96.Google Scholar
Mathers, C., Fat, D. M., Boerma, J. T. and World Health Organization (2008). The Global Burden of Disease: 2004 Update. Geneva: World Health Organization.Google Scholar
Medical Research Council (1965). Clinical trial of the treatment of depressive illness: report to the medical research council by its clinical psychiatry committee. The British Medical Journal, 1, 881–886.Google Scholar
Moore, R. C., Eyler, L. T., Mills, P. J., O'hara, R. M., Wachmann, K. and Laveretsky, H. (2015). Biology of positive psychiatry. In Jeste, D. V. and Palmer, B. W. (eds.), Positive Psychiatry, 1st edn (pp. 261–283). Washington, DC: American Psychiatric Publishing.Google Scholar
Nyström, S. (1964). On relation between clinical factors and efficacy of ECT in depression. Acta Psychiatrica Scandinavica, 40 (Suppl. 181), 1–140.Google Scholar
Ottosson, J. O. (1960). Experimental studies of the mode of action of electroconvulsive therapy. Acta Psychiatrica et Neurologica Scandinavica, 35 (supplementum 145), 5–131.Google Scholar
Ottosson, J. O. (1985). Use and misuse of electroconvulsive treatment. Biological Psychiatry, 20, 933–946.Google Scholar
Rasch, G. (1980). Probablistic Models for Some Intelligence and Attainment Tests. Expanded Edition. Chicago: Chicago University Press.Google Scholar
Rush, A. J. et al. (1995). Clinical characteristics of outpatients with chronic major depression. Journal of Affective Disorders, 34, 25–32.Google Scholar
Sim, K., Lau, W. K., Sim, J., Sum, M. Y. and Baldessarini, R. J. (2016). Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. The International Journal of Neuropsychopharmacology, 19, 1–13. doi:10.1093/ijnp/pyv076.Google Scholar
Timmerby, N., Andersen, J. H., Søndergaard, S., Østergaard, S. D. and Bech, P. (2017). A systematic review of the clinometric properties of the 6-item version of the Hamilton depression rating scale (HAM-D6). Psychother Psychosom, 86, 141–149.Google Scholar
Topp, C. W., Ostergaard, S. D., Sondergaard, S. and Bech, P. (2015). The WHO-5 well-being index: a systematic review of the literature. Psychotherapy and Psychosomatics, 84, 167–176.Google Scholar
UK ECT Review Group (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet, 361, 799–808.Google Scholar
Veldhuijzen, D. S. et al. (2006). Acute and subchronic effects of amitriptyline 25 mg on actual driving in chronic neuropathic pain patients. Journal of Psychopharmacology, 20, 782–788.Google Scholar
Wisniewski, S. R., Rush, A. J., Balasubramani, G. K., Trivedi, M. H., Nierenberg, A. A. and STARD Investigators (2006). Self-rated global measure of the frequency, intensity, and burden of side effects. Journal of Psychiatric Practice, 12, 71–79.Google ScholarPubMed
World Health Organization (1992). International Classification of Disease. Tenth Revision (ICD-10).Clinical Description and Diagnostic Guidelines. Geneva: World Health Organization.Google Scholar
Supplementary material: File

Bech supplementary material

Appendices 1-3

Download Bech supplementary material(File)
File 102 KB